| Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2 KM Zak, P Grudnik, K Magiera, A Dömling, G Dubin, TA Holak Structure 25 (8), 1163-1174, 2017 | 322 | 2017 |
| Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1 K Guzik, KM Zak, P Grudnik, K Magiera, B Musielak, R Torner, L Skalniak, ... Journal of Medicinal Chemistry 60 (13), 5857-5867, 2017 | 290 | 2017 |
| Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells L Skalniak, KM Zak, K Guzik, K Magiera, B Musielak, M Pachota, ... Oncotarget 8 (42), 72167, 2017 | 256 | 2017 |
| Bioactive macrocyclic inhibitors of the PD‐1/PD‐L1 immune checkpoint K Magiera‐Mularz, L Skalniak, KM Zak, B Musielak, E Rudzinska‐Szostak, ... Angewandte Chemie International Edition 56 (44), 13732-13735, 2017 | 162 | 2017 |
| CA-170–a potent small-molecule PD-L1 inhibitor or not? B Musielak, J Kocik, L Skalniak, K Magiera-Mularz, D Sala, M Czub, ... Molecules 24 (15), 2804, 2019 | 123 | 2019 |
| A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018) S Shaabani, HPS Huizinga, R Butera, A Kouchi, K Guzik, ... Expert opinion on therapeutic patents 28 (9), 665-678, 2018 | 123 | 2018 |
| Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies? M Konstantinidou, T Zarganes‐Tzitzikas, K Magiera‐Mularz, TA Holak, ... Angewandte Chemie International Edition 57 (18), 4840-4848, 2018 | 123 | 2018 |
| Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 … S Basu, J Yang, B Xu, K Magiera-Mularz, L Skalniak, B Musielak, ... Journal of medicinal chemistry 62 (15), 7250-7263, 2019 | 81 | 2019 |
| Multifaceted interplay between lipophilicity, protein interaction and luminescence parameters of non-intercalative ruthenium (II) polypyridyl complexes controlling cellular … O Mazuryk, K Magiera, B Rys, F Suzenet, C Kieda, M Brindell JBIC Journal of Biological Inorganic Chemistry 19, 1305-1316, 2014 | 67 | 2014 |
| Di-bromo-based small-molecule inhibitors of the PD-1/PD-L1 immune checkpoint M Konieczny, B Musielak, J Kocik, L Skalniak, D Sala, M Czub, ... Journal of Medicinal Chemistry 63 (19), 11271-11285, 2020 | 55 | 2020 |
| Lithocholic acid hydroxyamide destabilizes cyclin D1 and induces G0/G1 arrest by inhibiting deubiquitinase USP2a K Magiera, M Tomala, K Kubica, V De Cesare, M Trost, BJ Zieba, ... Cell chemical biology 24 (4), 458-470. e18, 2017 | 49 | 2017 |
| Terphenyl-based small-molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein–protein interaction D Muszak, E Surmiak, J Plewka, K Magiera-Mularz, J Kocik-Krol, ... Journal of medicinal chemistry 64 (15), 11614-11636, 2021 | 48 | 2021 |
| Human and mouse PD-L1: similar molecular structure, but different druggability profiles K Magiera-Mularz, J Kocik, B Musielak, J Plewka, D Sala, M Machula, ... Iscience 24 (1), 2021 | 48 | 2021 |
| Design, synthesis, and biological evaluation of imidazopyridines as PD-1/PD-L1 antagonists R Butera, M Ważyńska, K Magiera-Mularz, J Plewka, B Musielak, ... ACS Medicinal Chemistry Letters 12 (5), 768-773, 2021 | 36 | 2021 |
| Identification of small-molecule inhibitors of USP2a MD Tomala, K Magiera-Mularz, K Kubica, S Krzanik, B Zieba, B Musielak, ... European Journal of Medicinal Chemistry 150, 261-267, 2018 | 26 | 2018 |
| PD-L1 inhibitors: different classes, activities, and mechanisms of action E Surmiak, K Magiera-Mularz, B Musielak, D Muszak, J Kocik-Krol, R Kitel, ... International Journal of Molecular Sciences 22 (21), 11797, 2021 | 22 | 2021 |
| Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode P Niedziałkowski, M Bojko, J Ryl, A Wcisło, M Spodzieja, ... Bioelectrochemistry 139, 107742, 2021 | 18 | 2021 |
| Competition NMR for detection of hit/lead inhibitors of protein–protein interactions B Musielak, W Janczyk, I Rodriguez, J Plewka, D Sala, K Magiera-Mularz, ... Molecules 25 (13), 3017, 2020 | 15 | 2020 |
| Macrocyclic Peptide Inhibitor of PD‐1/PD‐L1 Immune Checkpoint K Magiera‐Mularz, K Kuska, L Skalniak, P Grudnik, B Musielak, J Plewka, ... Advanced Therapeutics 4 (2), 2000195, 2021 | 11 | 2021 |
| Imaging of clear cell renal carcinoma with immune checkpoint targeting aptamer-based probe S Malicki, B Pucelik, E Żyła, M Benedyk-Machaczka, W Gałan, A Golda, ... Pharmaceuticals 15 (6), 697, 2022 | 9 | 2022 |
